Improved EU Patient Access & Reimbursement On The Cards For Translarna

Some reimbursement agencies in Europe have been misinterpreting Translarna’s label and stopping access to the drug for boys with Duchenne muscular dystrophy who have been taking it but whose disease has progressed, PTC says.

Document with title reimbursement
Amended label for Translarna should improve continued access to the DMD drug • Source: Shutterstock

PTC Therapeutics is hoping that a recommendation by the European Medicines Agency to update the label of its approved Duchenne muscular dystrophy (DMD) treatment, Translarna (ataluren), will lead to improved patient access and reimbursement for the product across Europe.

The update aims to prevent reimbursement agencies from misinterpreting Translarna’s label and ceasing access to the drug in boys who...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet